You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 13, 2024

CLINICAL TRIALS PROFILE FOR SPARSENTAN

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Sparsentan

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01613118 ↗	Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis	Active, not recruiting	Retrophin, Inc.	Phase 2	2014-03-01	This study will investigate whether RE-021 (Sparsentan), a selective dual-acting receptor antagonist with affinity for endothelin (A type) and angiotensin II receptors (Type 1), is safe and effective in treating patients with focal segmental glomerulosclerosis (FSGS).
NCT01613118 ↗	Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis	Active, not recruiting	Travere Therapeutics, Inc.	Phase 2	2014-03-01	This study will investigate whether RE-021 (Sparsentan), a selective dual-acting receptor antagonist with affinity for endothelin (A type) and angiotensin II receptors (Type 1), is safe and effective in treating patients with focal segmental glomerulosclerosis (FSGS).
NCT03493685 ↗	Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)	Active, not recruiting	Retrophin, Inc.	Phase 3	2018-03-29	To determine the long-term nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with primary and genetic focal segmental glomerulosclerosis (FSGS).
NCT03493685 ↗	Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)	Active, not recruiting	Travere Therapeutics, Inc.	Phase 3	2018-03-29	To determine the long-term nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with primary and genetic focal segmental glomerulosclerosis (FSGS).
NCT03762850 ↗	A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy	Active, not recruiting	Retrophin, Inc.	Phase 3	2018-12-20	To determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN).
NCT03762850 ↗	A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy	Active, not recruiting	Travere Therapeutics, Inc.	Phase 3	2018-12-20	To determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN).
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Sparsentan

Condition Name

Chart
Table

Condition Name for Sparsentan
Intervention	Trials
Immunoglobulin A Nephropathy	4
Focal Segmental Glomerulosclerosis	3
Kidney Diseases	2
Immune System Diseases	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Sparsentan
Intervention	Trials
Glomerulonephritis, IGA	4
Kidney Diseases	3
Glomerulosclerosis, Focal Segmental	3
Vasculitis	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Sparsentan

Trials by Country

Map
Table

Trials by Country for Sparsentan
Location	Trials
United States	82
United Kingdom	23
Australia	10
Germany	9
Spain	8
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Sparsentan
Location	Trials
New York	4
Florida	4
Colorado	4
Wisconsin	3
Washington	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Sparsentan

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Sparsentan
Clinical Trial Phase	Trials
Phase 3	2
Phase 2	5
Phase 1	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Sparsentan
Clinical Trial Phase	Trials
Recruiting	3
Active, not recruiting	3
Completed	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Sparsentan

Sponsor Name

Chart
Table

Sponsor Name for Sparsentan
Sponsor	Trials
Travere Therapeutics, Inc.	8
Retrophin, Inc.	3
University of Leicester	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Sparsentan
Sponsor	Trials
Industry	11
Other	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.